CNC vs. EXEL: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CNC and EXEL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CNC | EXEL |
|---|---|---|
| Company Name | Centene Corporation | Exelixis, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 18.40 billion USD | 11.57 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | December 13, 2001 | April 17, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CNC and EXEL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CNC | EXEL |
|---|---|---|
| 5-Day Price Return | 6.22% | 0.58% |
| 13-Week Price Return | 27.69% | 8.72% |
| 26-Week Price Return | -38.31% | 12.72% |
| 52-Week Price Return | -37.32% | 18.36% |
| Month-to-Date Return | 2.86% | 7.71% |
| Year-to-Date Return | -39.95% | 25.08% |
| 10-Day Avg. Volume | 10.00M | 3.18M |
| 3-Month Avg. Volume | 14.43M | 2.91M |
| 3-Month Volatility | 53.24% | 39.61% |
| Beta | 0.47 | 0.39 |
Profitability
Return on Equity (TTM)
CNC
-20.61%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
CNC has a negative Return on Equity of -20.61%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
EXEL
31.64%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
In the upper quartile for the Biotechnology industry, EXEL’s Return on Equity of 31.64% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
CNC
-2.85%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
CNC has a negative Net Profit Margin of -2.85%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
EXEL
29.63%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
A Net Profit Margin of 29.63% places EXEL in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
CNC
-3.07%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
CNC has a negative Operating Profit Margin of -3.07%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
EXEL
34.97%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
An Operating Profit Margin of 34.97% places EXEL in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | CNC | EXEL |
|---|---|---|
| Return on Equity (TTM) | -20.61% | 31.64% |
| Return on Assets (TTM) | -6.26% | 24.03% |
| Net Profit Margin (TTM) | -2.85% | 29.63% |
| Operating Profit Margin (TTM) | -3.07% | 34.97% |
| Gross Profit Margin (TTM) | 8.14% | 96.63% |
Financial Strength
Current Ratio (MRQ)
CNC
1.08
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
CNC’s Current Ratio of 1.08 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
EXEL
3.75
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
EXEL’s Current Ratio of 3.75 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CNC
0.84
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
CNC’s Debt-to-Equity Ratio of 0.84 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
EXEL
0.00
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
EXEL’s Debt-to-Equity Ratio of 0.00 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
CNC
7.06
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
CNC’s Interest Coverage Ratio of 7.06 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
EXEL
42.74
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
EXEL’s Interest Coverage Ratio of 42.74 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | CNC | EXEL |
|---|---|---|
| Current Ratio (MRQ) | 1.08 | 3.75 |
| Quick Ratio (MRQ) | 1.08 | 3.47 |
| Debt-to-Equity Ratio (MRQ) | 0.84 | 0.00 |
| Interest Coverage Ratio (TTM) | 7.06 | 42.74 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CNC
0.00%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
CNC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CNC
0.00%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
CNC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
EXEL
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXEL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CNC | EXEL |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CNC
--
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
P/E Ratio data for CNC is currently unavailable.
EXEL
16.96
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
EXEL’s P/E Ratio of 16.96 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
CNC
0.10
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, CNC’s P/S Ratio of 0.10 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
EXEL
5.02
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
EXEL’s P/S Ratio of 5.02 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
CNC
0.84
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
CNC’s P/B Ratio of 0.84 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
EXEL
4.99
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
EXEL’s P/B Ratio of 4.99 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | CNC | EXEL |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 16.96 |
| Price-to-Sales Ratio (TTM) | 0.10 | 5.02 |
| Price-to-Book Ratio (MRQ) | 0.84 | 4.99 |
| Price-to-Free Cash Flow Ratio (TTM) | 4.47 | 14.74 |